ArriVent BioPharma enters ADC collaboration with Alphamab; milestones up to $615.5M

ArriVent BioPharma, Inc.

Collaboration to discover, develop, and commercialize novel antibody drug conjugates (ADCs) for cancers.
Total upfront and milestone payments to Alphamab up to $615.5 million plus tiered sales royalties.
ArriVent gains exclusive rights to develop and commercialize ADCs outside greater China; Alphamab retains greater China rights.
Deal leverages Alphamab's proprietary linker-payload platform and glycan-conjugation technology.
ArriVent CEO Bing Yao cites potential to add multiple innovative ADC programs to pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.